Henlius’ Trastuzumab Approved In China
Becomes First China-Developed mAb Biosimilar Approved In Both China And EU
Shanghai Henlius Biotech has received the first Chinese approval for a trastuzumab biosimilar version of Herceptin.
You may also be interested in...
Henlius has reshuffled its C-suite, with chairman Qiyu Chen stepping down from the role to take up a position as non-executive director and CEO Wenjie Zhang poised to step into his shoes.
Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.
After receiving approval from the Chinese regulatory body for rituximab and trastuzumab, Shanghai Henlius Biotech has now received approval for its HLX03 adalimumab biosimilar rival to Humira. The company has partnered with Wanbang Biopharma for commercialization of HLX03 in China.